Clinical Trials

Numerous clinical trials spanning Early Phase 1 through Phase 4 have extensively evaluated Ibrutinib, predominantly targeting hematological malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström's macroglobulinemia, and primary central nervous system lymphoma. Supported by academic, cooperative, and pharmaceutical sponsors, these monotherapy and combination studies encompass diverse recruitment statuses, including active, completed, and terminated. Ultimately, these investigations focus on assessing the efficacy, safety profiles, and therapeutic outcomes across primary, recurrent, and refractory B-cell lymphoproliferative disorders.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07474961 NOT_YET_RECRUITING
Waldenstrom Macroglobulinaemia; Multiple Myeloma
Anne Louise Tølbøll Sørensen
 2027-03 PHASE4
NCT04446962 ACTIVE_NOT_RECRUITING
Lymphoma, Large B-Cell, Diffuse; Central Nervous System Neoplasms, Primary
Institut Curie
 2020-10-30 PHASE1; PHASE2
NCT05283720 ACTIVE_NOT_RECRUITING
Non-Hodgkin Lymphoma
Genmab
 2022-06-14 PHASE2
NCT06136559 RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
 2023-12-13 PHASE3
NCT06482684 RECRUITING
Mantle Cell Lymphoma
Christian Schmidt, MD
 2024-02-15 PHASE2
NCT07377578 RECRUITING
Mantle Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
 2026-02-05 PHASE3
NCT06520098 RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
VA Office of Research and Development
 2025-10-01 PHASE2
NCT04061512 RECRUITING
Waldenstrom Macroglobulinemia
University College, London
 2020-02-03 PHASE2; PHASE3
NCT07738887 NOT_YET_RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
The Lymphoma Academic Research Organisation
 2026-12-31 PHASE2
NCT01841723 ACTIVE_NOT_RECRUITING
Hairy Cell Leukemia; Hairy Cell Leukemia Variant; Recurrent Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia Variant
National Cancer Institute (NCI)
 2013-04-30 PHASE2
NCT07052695 RECRUITING
Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
Inhye Ahn
 2025-11-24 PHASE1; PHASE2
NCT03964090 ACTIVE_NOT_RECRUITING
Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma
National Cancer Institute (NCI)
 2019-06-27 PHASE2
NCT06649812 RECRUITING
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
National Cancer Institute (NCI)
 2025-10-07 PHASE2
NCT07169565 NOT_YET_RECRUITING
Waldenström Macroglobulinemia (WM)
Institute of Hematology & Blood Diseases Hospital, China
 2025-09-01 PHASE1
NCT07082868 RECRUITING
Primary Central Nervous System Lymphoma (PCNSL); Primary Central Nervous System Lymphoma; Relapsed Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma; Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
 2025-08-13 PHASE1
NCT01880567 ACTIVE_NOT_RECRUITING
CCND1 Positive; CCND2 Positive; CCND3 Positive; CD20 Positive; Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
 2013-07-15 PHASE2
NCT02007044 ACTIVE_NOT_RECRUITING
Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
 2013-12-06 PHASE2
NCT05998642 RECRUITING
Non-hodgkin Lymphoma
Canadian Cancer Trials Group
 2024-02-13 PHASE2
NCT03701282 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
 2019-02-12 PHASE3
NCT04263480 ACTIVE_NOT_RECRUITING
Waldenstrom Macroglobulinemia
Christian Buske
 2021-08-18 PHASE2
NCT04840602 RECRUITING
Lymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
National Cancer Institute (NCI)
 2022-01-05 PHASE2
NCT02629809 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
 2016-03-18 PHASE2
NCT05106296 RECRUITING
Ependymoma; Medulloblastoma; Glioblastoma; Primary Brain Tumor
Theodore S. Johnson
 2022-02-08 PHASE1
NCT03282396 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
M.D. Anderson Cancer Center
 2020-06-08 PHASE2
NCT05963074 ACTIVE_NOT_RECRUITING
Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
 2024-05-30 PHASE2
NCT06958705 RECRUITING
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
The First Affiliated Hospital with Nanjing Medical University
 2025-12-01 PHASE2
NCT03331198 ACTIVE_NOT_RECRUITING
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic
Juno Therapeutics, a Subsidiary of Celgene
 2017-11-27 PHASE1; PHASE2
NCT06357676 RECRUITING
Mantle Cell Lymphoma
OHSU Knight Cancer Institute
 2025-05-29 PHASE1; PHASE2
NCT05254743 RECRUITING
Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic; Leukemia, B-cell; Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
 2022-07-22 PHASE3
NCT04234061 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma Recurrent
Peter MacCallum Cancer Centre, Australia
 2020-04-07 PHASE2
NCT04608318 ACTIVE_NOT_RECRUITING
Chronic Lymphoid Leukemia
German CLL Study Group
 2021-03-01 PHASE3
NCT06536049 RECRUITING
Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Grade 3b Follicular Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma
Yazeed Sawalha
 2025-04-02 PHASE1; PHASE2
NCT02756897 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
 2016-07-07 PHASE2
NCT04189757 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
M.D. Anderson Cancer Center
 2020-08-07 PHASE2
NCT03960840 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Large B-cell Lymphoma; Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
Novartis Pharmaceuticals
 2019-06-26 PHASE1; PHASE2
NCT02427620 ACTIVE_NOT_RECRUITING
Blastoid Variant Mantle Cell Lymphoma; Mantle Cell Lymphoma; Pleomorphic Variant Mantle Cell Lymphoma
M.D. Anderson Cancer Center
 2015-06-03 PHASE2
NCT03697512 ACTIVE_NOT_RECRUITING
Marginal Zone Lymphoma; Nodal Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
 2019-09-27 PHASE2
NCT03128879 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
 2017-06-16 PHASE2
NCT03229200 ACTIVE_NOT_RECRUITING
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, B-cell; Graft Vs Host Disease; Solid Tumor
Pharmacyclics Switzerland GmbH
 2017-05-22 PHASE4
NCT04450173 ACTIVE_NOT_RECRUITING
Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma
University of California, Davis
 2021-02-24 PHASE2
NCT03710772 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
M.D. Anderson Cancer Center
 2019-05-01 PHASE2
NCT04212013 ACTIVE_NOT_RECRUITING
Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
 2019-12-23 PHASE3
NCT04662255 ACTIVE_NOT_RECRUITING
Lymphoma, Mantle-Cell
Loxo Oncology, Inc.
 2021-04-08 PHASE3
NCT01804686 RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B-cell Lymphoma; Waldenstrom Macroglobulinemia; Chronic Graft Versus Host Disease
Janssen Research & Development, LLC
 2013-09-09 PHASE3
NCT02436707 ACTIVE_NOT_RECRUITING
Lymphoma
Canadian Cancer Trials Group
 2015-10-27 PHASE2
NCT03513562 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Ibrutinib Resistance
Ohio State University Comprehensive Cancer Center
 2019-03-26 PHASE2
NCT06757647 RECRUITING
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Seema Bhat
 2025-05-27 PHASE2
NCT04421560 RECRUITING
Primary Central Nervous System Lymphoma; Recurrent Cancer; Refractory Cancer; Relapsed Cancer
Dana-Farber Cancer Institute
 2020-08-01 PHASE1; PHASE2
NCT03223610 RECRUITING
Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Burkitt Lymphoma
National Cancer Institute (NCI)
 2018-02-09 PHASE1; PHASE2
NCT04509700 ACTIVE_NOT_RECRUITING
B-Cell Malignancies
Incyte Corporation
 2020-08-03 PHASE2
NCT03479268 ACTIVE_NOT_RECRUITING
B-Cell Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Small Lymphocytic Lymphoma; Richter Syndrome
City of Hope Medical Center
 2018-04-27 PHASE1
NCT05431179 WITHDRAWN
Lymphoma, Mantle-Cell; Lymphoma; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell
Oncternal Therapeutics, Inc
 2023-03 PHASE3
NCT04908228 RECRUITING
Chronic Lymphocytic Leukemia
Paolo Ghia
 2021-12-13 PHASE2
NCT05672173 ACTIVE_NOT_RECRUITING
Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome
City of Hope Medical Center
 2023-06-02 PHASE2
NCT02203526 ACTIVE_NOT_RECRUITING
Primary Central Nervous System Lymphoma
National Cancer Institute (NCI)
 2014-08-14 PHASE1
NCT02940301 ACTIVE_NOT_RECRUITING
Classical Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
 2016-12-20 PHASE2
NCT03328078 RECRUITING
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy; Relapsed Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma
Curis, Inc.
 2017-12-28 PHASE1; PHASE2
NCT05864742 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma Refractory
Peter MacCallum Cancer Centre, Australia
 2023-09-07 PHASE2
NCT03447808 COMPLETED
Chronic Lymphocytic Leukemia
Jennifer Woyach
 2018-08-16 PHASE1
NCT06271616 TERMINATED
Chronic Graft Versus Host Disease; Hematopoietic and Lymphatic System Neoplasm
Mayo Clinic
 2024-12-13 PHASE2
NCT04739813 ACTIVE_NOT_RECRUITING
Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Burkitt Lymphoma
National Cancer Institute (NCI)
 2021-07-09 PHASE1
NCT02787369 ACTIVE_NOT_RECRUITING
Recurrent Chronic Lymphoid Leukemia
Dana-Farber Cancer Institute
 2016-05 PHASE1
NCT03581942 COMPLETED
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Memorial Sloan Kettering Cancer Center
 2018-08-23 PHASE1; PHASE2
NCT02315326 COMPLETED
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL); Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
 2014-12-08 PHASE1; PHASE2
NCT03703167 COMPLETED
Primary Central Nervous System Lymphoma (PCNSL); Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center
 2019-01-22 PHASE1
NCT04116437 COMPLETED
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
BeiGene
 2019-10-15 PHASE2
NCT03021460 COMPLETED
Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
Mayo Clinic
 2017-01-31 PHASE1
NCT03478514 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma; B Cell Lymphoma
Alliance Foundation Trials, LLC.
 2018-09-11 PHASE2
NCT02518555 COMPLETED
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Jennifer Woyach
 2016-01-12 PHASE2
NCT04639362 ACTIVE_NOT_RECRUITING
CLL
Stichting Hemato-Oncologie voor Volwassenen Nederland
 2020-12-29 PHASE2
NCT04607772 WITHDRAWN
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc
 2020-11-18 PHASE1; PHASE2
NCT03708003 TERMINATED
Relapsed/Refractory Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Leukemia
Swiss Cancer Institute
 2019-03-11 PHASE2
NCT03153202 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
Joshua Brody
 2017-07-14 PHASE1; PHASE2
NCT05105841 COMPLETED
Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
AbbVie
 2021-11-08 PHASE2
NCT03790332 COMPLETED
Chronic Graft Versus Host Disease
Pharmacyclics LLC.
 2018-11-19 PHASE1; PHASE2
NCT02997761 COMPLETED
Adult B Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive
University of California, Davis
 2017-06-27 PHASE2
NCT04802590 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
The Lymphoma Academic Research Organisation
 2022-01-24 PHASE2
NCT02005289 COMPLETED
Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
 2014-01-17 PHASE2
NCT05694312 RECRUITING
Autoimmune Hemolytic Anemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Monoclonal B-Cell Lymphocytosis CLL-Type
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2023-11-24 PHASE2
NCT03939182 COMPLETED
Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
 2019-05-29 PHASE1
NCT04781855 WITHDRAWN
Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome
M.D. Anderson Cancer Center
 2022-07-14 PHASE1
NCT04876092 COMPLETED
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin
Janssen Research & Development, LLC
 2021-07-28 PHASE1
NCT03770416 COMPLETED
Central Nervous System B-Cell Non-Hodgkin Lymphoma; Recurrent Central Nervous System Lymphoma; Refractory Central Nervous System Lymphoma
M.D. Anderson Cancer Center
 2019-02-15 PHASE2
NCT03737981 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
 2019-01-31 PHASE3
NCT02251548 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Leukemia
Dana-Farber Cancer Institute
 2014-10 PHASE2
NCT03379428 ACTIVE_NOT_RECRUITING
Breast Neoplasms; Malignant Neoplasm of Breast
US Oncology Research
 2017-11-29 PHASE1; PHASE2
NCT04398459 ACTIVE_NOT_RECRUITING
Refractory/Relapsed Autoimmune Hemolytic Anemia
Institute of Hematology & Blood Diseases Hospital, China
 2020-05-01 PHASE2
NCT04758975 RECRUITING
Chronic Lymphocytic Leukemia (CLL)
Paolo Ghia
 2022-09-19 PHASE2
NCT03129828 COMPLETED
Diffuse Large B Cell Lymphoma
Prof. Dr. Clemens Schmitt
 2017-03-17 PHASE1; PHASE2
NCT01955499 ACTIVE_NOT_RECRUITING
Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma
National Cancer Institute (NCI)
 2013-09-24 PHASE1
NCT04494503 RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
 2020-08-31 PHASE1; PHASE2
NCT04688385 COMPLETED
Chronic Lymphocytic Leukemia
University Hospital Tuebingen
 2020-12-23 PHASE1
NCT03220022 ACTIVE_NOT_RECRUITING
AIDS-Related Lymphoma; Ann Arbor Stage II Diffuse Large B-Cell Lymphoma; Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
 2018-03-16 PHASE1
NCT04939363 COMPLETED
Richter's Syndrome
Bnai Zion Medical Center
 2021-08-08 PHASE2
NCT03702725 COMPLETED
Refractory Multiple Myeloma; Multiple Myeloma in Relapse; Multiple Myeloma
Alliance Foundation Trials, LLC.
 2019-08-29 PHASE1
NCT03088878 COMPLETED
B-cell Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma
Oncternal Therapeutics, Inc
 2018-01-03 PHASE1; PHASE2
NCT04992377 UNKNOWN
Richter Transformation
Institute of Hematology & Blood Diseases Hospital, China
 2021-08-30 PHASE2
NCT05491044 UNKNOWN
CLL/SLL
Peking University People's Hospital
 2022-01-01 PHASE2
NCT03207555 COMPLETED
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
 2018-05-23 PHASE2
NCT03422393 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Michael Choi
 2018-05-01 PHASE1
NCT03731234 ACTIVE_NOT_RECRUITING
DLBCL
Fondazione Italiana Linfomi - ETS
 2019-07-02 PHASE2
NCT03112174 COMPLETED
Mantle-Cell Lymphoma
Pharmacyclics LLC.
 2017-06-19 PHASE3
NCT03440567 COMPLETED
Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mantle Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
 2018-04-02 PHASE1
NCT04294641 COMPLETED
Chronic GVHD
National Cancer Institute (NCI)
 2021-05-10 PHASE2
NCT02443077 ACTIVE_NOT_RECRUITING
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
National Cancer Institute (NCI)
 2016-10-12 PHASE3
NCT05211336 ACTIVE_NOT_RECRUITING
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS); Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
National Cancer Institute (NCI)
 2022-04-19 PHASE1
NCT06084923 Not yet recruiting
Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell''Adulto
 2024-05 --
NCT02388048 COMPLETED
Leukemia, Lymphoblastic, Chronic
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2015-10 PHASE2
NCT04042376 COMPLETED
Waldenstrom Macroglobulinemia
Janssen Research & Development, LLC
 2019-12-18 PHASE4
NCT06224452 Not yet recruiting
Hematological Malignancy|Atrial Fibrillation
University Hospital Caen
 2024-03-01 --
NCT02950051 COMPLETED
Chronic Lymphocytic Leukemia
German CLL Study Group
 2016-12-13 PHASE3
NCT02947347 COMPLETED
Follicular Lymphoma
Pharmacyclics LLC.
 2017-01-23 PHASE3
NCT04260217 COMPLETED
Waldenstrom Macroglobulinemia
Ascentage Pharma Group Inc.
 2021-05-30 PHASE1
NCT03295240 COMPLETED
Mantle Cell Lymphoma; Lymphoma
Memorial Sloan Kettering Cancer Center
 2017-09-20 EARLY_PHASE1
NCT04129710 UNKNOWN
Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
 2020-01-01 PHASE2
NCT03399513 COMPLETED
Diffuse Large B Cell Lymphoma
University Hospital Muenster
 2018-05-03 PHASE2
NCT02649387 COMPLETED
Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia
Mayo Clinic
 2016-02-08 PHASE2
NCT05564052 COMPLETED
Lymphoma, Mantle-Cell
Janssen Research & Development, LLC
 2022-12-06 PHASE2
NCT02623010 UNKNOWN
Central Nervous System Lymphoma
Rabin Medical Center
 2016-10 PHASE2
NCT02207062 COMPLETED
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Refractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington
 2014-10 PHASE2
NCT05694312 Recruiting
Autoimmune Hemolytic Anemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Monoclonal B-Cell Lymphocytosis CLL-Type
Gruppo Italiano Malattie EMatologiche dell''Adulto
 2023-11-24 Phase 2
NCT03198026 ACTIVE_NOT_RECRUITING
Non-Hodgkin's Lymphoma; Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage II Nodal Marginal Zone Lymphoma; Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage III Nodal Marginal Zone Lymphoma; Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma; Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Ann Arbor Stage IV Follicular Lymphoma; Ann Arbor Stage IV Nodal Marginal Zone Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Indolent Non-hodgkin Lymphoma; Stage II Splenic Marginal Zone Lymphoma; Stage III Splenic Marginal Zone Lymphoma; Stage IV Splenic Marginal Zone Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
 2018-02-20 PHASE2
NCT03400176 TERMINATED
Chronic Lymphocytic Leukemia (CLL)
Novartis Pharmaceuticals
 2018-04-09 PHASE1
NCT01724346 COMPLETED
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Pharmacyclics LLC.
 2013-12-03 PHASE3
NCT02532257 COMPLETED
Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage II Marginal Zone Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage III Marginal Zone Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Ann Arbor Stage IV Marginal Zone Lymphoma; CD20 Positive; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma
M.D. Anderson Cancer Center
 2016-04-11 PHASE2
NCT04522284 UNKNOWN
Solid Tumor
National University Hospital, Singapore
 2020-08-20 PHASE1; PHASE2
NCT02955628 UNKNOWN
Diffuse Large B Cell Lymphoma; Diffuse Large B-Cell Lymphoma Recurrent
Singapore General Hospital
 2016-12-13 PHASE2
NCT03219047 COMPLETED
Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
 2018-12-20 EARLY_PHASE1
NCT03734198 ACTIVE_NOT_RECRUITING
Relapsed or Refractory Chronic Lymphocytic Leukemia
French Innovative Leukemia Organisation
 2018-12-19 PHASE2
NCT02956382 COMPLETED
Refractory Follicular Lymphoma; Relapsed Follicular Lymphoma
Georgetown University
 2017-03-01 PHASE1; PHASE2
NCT02927964 COMPLETED
Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma
Robert Lowsky
 2016-11-07 PHASE1; PHASE2
NCT03514017 TERMINATED
Chronic Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
 2019-05-31 PHASE2
NCT02824029 COMPLETED
Classical Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
 2016-06 PHASE2
NCT02309580 COMPLETED
T-cell Lymphoma; Relapsed and Refractory T-cell Lymphoma
Memorial Sloan Kettering Cancer Center
 2015-01 PHASE1
NCT03190330 COMPLETED
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell
Johnson & Johnson Private Limited
 2019-06-26 PHASE4
NCT04230304 TERMINATED
Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
Mayo Clinic
 2020-11-11 PHASE2
NCT02643667 COMPLETED
Prostate Cancer
Washington University School of Medicine
 2016-07 PHASE2
NCT03535350 ACTIVE_NOT_RECRUITING
Glioblastoma
Case Comprehensive Cancer Center
 2018-08-24 PHASE1
NCT04010968 COMPLETED
Intermediate Risk Chronic Lymphocytic Leukemia; Fit Patients; Risk-Adapted and MRD-Driven Strategy
French Innovative Leukemia Organisation
 2019-09-27 PHASE2
NCT04771507 RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Jeanette Lundin
 2018-02-23 PHASE1; PHASE2
NCT05348096 UNKNOWN
Chronic Graft-versus-host-disease
Hospital Universitario Dr. Jose E. Gonzalez
 2022-04-01 PHASE2
NCT04685915 WITHDRAWN
Chronic Lymphocytic Leukemia (CLL)
Inhye Ahn
 2021-02-18 PHASE2
NCT03310619 COMPLETED
Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular
Celgene
 2017-12-20 PHASE1; PHASE2
NCT03506373 TERMINATED
Recurrent Waldenstrom Macroglobulinemia; Refractory Waldenstrom Macroglobulinemia; Waldenstrom Macroglobulinemia
Mayo Clinic
 2018-08-14 PHASE2
NCT03617484 WITHDRAWN
Mantle Cell Lymphoma
University of Michigan Rogel Cancer Center
 2020-07 PHASE2
NCT03225716 TERMINATED
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
 2017-10-20 PHASE1
NCT04235036 TERMINATED
Graft Vs Host Disease
Northside Hospital, Inc.
 2019-12-16 PHASE2
NCT03980002 RECRUITING
Chronic Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
 2019-05-15 PHASE2
NCT02451111 TERMINATED
Follicular Lymphoma
Swiss Cancer Institute
 2015-11-06 PHASE2
NCT03620903 ACTIVE_NOT_RECRUITING
Waldenstrom Macroglobulinemia
Christian Buske
 2019-09-11 PHASE2
NCT03684694 TERMINATED
Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma
ADC Therapeutics S.A.
 2018-12-01 PHASE1; PHASE2
NCT02604511 COMPLETED
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
 2016-01 PHASE2
NCT04274738 COMPLETED
Waldenstrom's Macroglobulinemia
X4 Pharmaceuticals
 2020-04-30 PHASE1
NCT02636322 COMPLETED
Diffuse Large B-Cell Lymphoma Unclassifiable
M.D. Anderson Cancer Center
 2016-03-29 PHASE2
NCT03015792 TERMINATED
Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
Mayo Clinic
 2017-03-10 PHASE1
NCT03877055 COMPLETED
Mantle Cell Lymphoma (MCL)
Memorial Sloan Kettering Cancer Center
 2019-03-13 PHASE1; PHASE2
NCT02756247 COMPLETED
Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Diffuse Large B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
 2016-05-09 PHASE1
NCT03323151 COMPLETED
Mantle-Cell Lymphoma
PrECOG, LLC.
 2018-08-13 PHASE1; PHASE2
NCT04439006 COMPLETED
Aplastic Anemia; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Monoclonal B-Cell Lymphocytosis; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic Syndrome; Symptomatic COVID-19 Infection Laboratory-Confirmed
Jennifer Woyach
 2020-10-23 PHASE1
NCT04514393 UNKNOWN
Primary Central Nervous System Lymphoma; PCNSL; Non Hodgkin Lymphoma
Huiqiang Huang
 2020-10-10 PHASE2
NCT03734016 COMPLETED
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
BeiGene
 2018-11-01 PHASE3
NCT03642236 UNKNOWN
FLT3-ITD Mutation; Acute Myeloid Leukemia; Brutons Tyrosine Kinase
Nanfang Hospital, Southern Medical University
 2018-08 PHASE2; PHASE3
NCT03204188 COMPLETED
B-Cell Chronic Lymphocytic Leukemia; B-Lymphocytic Leukemia, Chronic; Chronic Lymphocytic Leukemia; Leukemia, Chronic Lymphatic; Leukemia, Chronic Lymphocytic, B-Cell; Leukemia, Lymphocytic, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytic Leukemia, Chronic, B Cell; Lymphocytic Leukemia, Chronic, B-Cell
National Heart, Lung, and Blood Institute (NHLBI)
 2017-09-22 PHASE2
NCT03424122 COMPLETED
B-cell Lymphoma
Incyte Corporation
 2018-07-02 PHASE1
NCT03053440 COMPLETED
Waldenström's Macroglobulinemia
BeiGene
 2017-01-25 PHASE3
NCT02760485 COMPLETED
Lymphoma
Incyte Corporation
 2016-12-29 PHASE1; PHASE2
NCT04273139 ACTIVE_NOT_RECRUITING
Waldenstrom Macroglobulinemia; MYD88 Gene Mutation
Dana-Farber Cancer Institute
 2020-07-09 PHASE2
NCT01974440 COMPLETED
Lymphoma
Janssen Research & Development, LLC
 2014-01-31 PHASE3
NCT04016805 TERMINATED
Chronic Lymphocytic Leukemia
TG Therapeutics, Inc.
 2019-08-05 PHASE2
NCT02315768 COMPLETED
Chronic Lymphocytic Leukemia
University of California, San Diego
 2015-08-26 PHASE1; PHASE2
NCT02303392 COMPLETED
Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia
Jennifer Woyach
 2015-06-09 PHASE1
NCT04994626 UNKNOWN
DLBCL; MYD88 Gene Mutation; CD79A Gene Mutation; CD79B Gene Mutation; Relapse; Refractory Lymphoma
Chinese Academy of Medical Sciences
 2021-10-01 PHASE2
NCT02689869 UNKNOWN
Indolent Non-Hodgkin Lymphoma
Ludwig-Maximilians - University of Munich
 2016-04 PHASE2
NCT03130348 WITHDRAWN
Amyloidosis; Immunoglobulin Light Chain Deposition
Mayo Clinic
 2018-03-15 PHASE2
NCT02420912 COMPLETED
Loss of Chromosome 17p; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome
M.D. Anderson Cancer Center
 2015-06-19 PHASE2
NCT03121534 TERMINATED
Hematopoietic/Lymphoid Cancer; Richter's Transformation
M.D. Anderson Cancer Center
 2017-06-22 PHASE2
NCT02329847 COMPLETED
Hematologic Neoplasms
Janssen Research & Development, LLC
 2015-03-11 PHASE1; PHASE2
NCT04477486 COMPLETED
Mantle Cell Lymphoma (MCL)
AbbVie
 2020-09-23 PHASE2
NCT02662296 WITHDRAWN
Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
 2016-03 PHASE2
NCT02758665 COMPLETED
Leukemia, Lymphocytic, Chronic
University of Ulm
 2016-09 PHASE2
NCT04115059 TERMINATED
Waldenstrom Macroglobulinemia; DASATINIB
Jorge J. Castillo, MD
 2019-11-04 PHASE1
NCT02884453 UNKNOWN
Gastrooesophageal Cancer
Royal Marsden NHS Foundation Trust
 2016-07-19 PHASE2
NCT02427451 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia
Kerry Rogers
 2015-08-03 PHASE1; PHASE2
NCT02242097 COMPLETED
Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Northwestern University
 2015-01-12 PHASE2
NCT03474679 COMPLETED
Graft vs Host Disease
Janssen Pharmaceutical K.K.
 2018-05-01 PHASE3
NCT04665115 WITHDRAWN
Asymptomatic COVID-19 Infection Laboratory-Confirmed; B-Cell Neoplasm; Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma; Symptomatic COVID-19 Infection Laboratory-Confirmed; Waldenstrom Macroglobulinemia
Academic and Community Cancer Research United
 2020-11-23 PHASE2
NCT02869633 COMPLETED
Blastoid Variant Mantle Cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Follicular Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Follicular Lymphoma; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma
Vanderbilt-Ingram Cancer Center
 2016-11 PHASE2
NCT03873493 COMPLETED
Leukemia; T-cell Prolymphocytic Leukemia (T-PLL); Cancer
AbbVie
 2020-01-14 PHASE2
NCT03876028 TERMINATED
Diffuse Large B-cell Lymphoma
Novartis Pharmaceuticals
 2019-06-11 PHASE1
NCT04066920 UNKNOWN
Primary Central Nervous System Lymphoma
Deok-Hwan Yang
 2019-10-01 PHASE2
NCT03689894 TERMINATED
Chronic Graft-versus-host-disease
Dartmouth-Hitchcock Medical Center
 2019-04-11 PHASE1; PHASE2
NCT02321540 COMPLETED
Lung Cancer
M.D. Anderson Cancer Center
 2015-03-31 PHASE1; PHASE2
NCT02581930 COMPLETED
Metastatic Melanoma; Recurrent Cutaneous Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7
National Cancer Institute (NCI)
 2016-12-16 PHASE2
NCT04062448 COMPLETED
Waldenstrom Macroglobulinemia
Janssen Pharmaceutical K.K.
 2019-09-25 PHASE2
NCT02599324 COMPLETED
Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma; Advanced Gastric Adenocarcinoma; Metastatic Colorectal Adenocarcinoma
Pharmacyclics LLC.
 2015-12-01 PHASE1; PHASE2
NCT02332980 COMPLETED
Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Follicular Lymphoma; Refractory Lymphoplasmacytic Lymphoma; Refractory Nodal Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Splenic Marginal Zone Lymphoma; Refractory Waldenstrom Macroglobulinemia; Richter Syndrome; Waldenstrom Macroglobulinemia
Mayo Clinic
 2015-02-19 PHASE2
NCT03943342 WITHDRAWN
Chronic Lymphocytic Leukemia; Loss of Chromosome 17p
Kerry Rogers
 2020-03-11 PHASE2
NCT04025593 UNKNOWN
Diffuse Large B Cell Lymphoma
Ruijin Hospital
 2019-07-17 PHASE2
NCT03232307 WITHDRAWN
CCND1 Positive; CD20-Positive Neoplastic Cells Present; Mantle Cell Lymphoma
M.D. Anderson Cancer Center
 2019-07-01 PHASE2
NCT03226301 UNKNOWN
Chronic Lymphocytic Leukemia in Relapse; Chronic Lymphocytic Leukemia in Remission
Stichting Hemato-Oncologie voor Volwassenen Nederland
 2017-06-23 PHASE2
NCT01776840 COMPLETED
Mantle Cell Lymphoma
Janssen Research & Development, LLC
 2013-05-16 PHASE3
NCT02703272 TERMINATED
Lymphoma, Non-Hodgkin
Janssen Research & Development, LLC
 2016-07-01 PHASE3
NCT02736617 COMPLETED
Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma
OHSU Knight Cancer Institute
 2016-07-05 PHASE2
NCT04375397 COMPLETED
CoronaVirus Induced Disease-2019 (COVID-19)
AbbVie
 2020-06-06 PHASE2
NCT02858258 UNKNOWN
Mantle Cell Lymphoma
Prof. Dr. M. Dreyling (co-chairman)
 2016-07 PHASE3
NCT02419560 COMPLETED
Lymphoma, Mantle-Cell; Recurrent Lymphoma, Mantle-Cell
Craig Portell, MD
 2015-04 PHASE1
NCT03267186 COMPLETED
Acute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic Cell Transplantation Recipient
Andrew Rezvani
 2017-09-12 PHASE2
NCT02356458 TERMINATED
Mantle Cell Lymphoma
Swiss Cancer Institute
 2015-08-31 PHASE1; PHASE2
NCT02744612 COMPLETED
Recurrent Hodgkin Lymphoma; Refractory Hodgkin Lymphoma
City of Hope Medical Center
 2016-06-20 PHASE2
NCT03949062 UNKNOWN
Diffuse Large B Cell Lymphoma
Ruijin Hospital
 2019-03-13 PHASE2
NCT03462719 ACTIVE_NOT_RECRUITING
Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
 2018-04-17 PHASE3
NCT04209621 TERMINATED
Small Lymphocytic Leukemia (SLL); Chronic Lymphocytic Leukemia (CLL)
National Heart, Lung, and Blood Institute (NHLBI)
 2020-07-31 PHASE2
NCT03454165 COMPLETED
Chronic Lymphocytic Leukemia
Dartmouth-Hitchcock Medical Center
 2018-03-09 PHASE1
NCT03755947 COMPLETED
B-Cell Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
Grupo Cooperativo de Hemopatías Malignas
 2018-12-01 PHASE2
NCT02077166 COMPLETED
Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC.
 2014-03-13 PHASE1; PHASE2
NCT02991638 UNKNOWN
Chronic Lymphocytic Leukemia; Indolent B-cell Lymphomas; Chronic Hepatitis B; Lymphoma, Small Lymphocytic; Mantle-Cell Lymphoma; Waldenstrom's Macroglobulinaemia; Follicular Lymphoma
The University of Hong Kong
 2016-11-01 PHASE3
NCT02471391 UNKNOWN
Mantle Cell Lymphoma
Peter MacCallum Cancer Centre, Australia
 2015-07-22 PHASE2
NCT01886859 COMPLETED
Recurrent B-Cell Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory B-Cell Prolymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
 2013-04-26 PHASE1
NCT02910583 COMPLETED
Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Pharmacyclics LLC.
 2016-09-28 PHASE2
NCT03136497 TERMINATED
Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
Hackensack Meridian Health
 2017-09-05 PHASE1
NCT02717611 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia
Acerta Pharma BV
 2016-03-08 PHASE2
NCT03679624 TERMINATED
Waldenstrom Macroglobulinemia; Waldenstrom's Disease; Waldenström; Hypergammaglobulinemia; Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia of Lymph Nodes; Waldenstrom's Macroglobulinaemia, Without Mention of Remission; Waldenstrom's Macroglobulinemia Refractory
Weill Medical College of Cornell University
 2020-07-30 PHASE2
NCT02477696 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia
Acerta Pharma BV
 2015-07-28 PHASE3
NCT03646461 TERMINATED
Head and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
University of California, San Diego
 2018-10-17 PHASE2
NCT02899078 COMPLETED
Metastatic Renal Cell Cancer; Stage IV Renal Cell Cancer
University of California, Davis
 2016-11-15 PHASE1; PHASE2
NCT02626884 COMPLETED
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
University of Cologne
 2016-08 PHASE2
NCT02954406 TERMINATED
Lymphoma, Non-Hodgkin
Millennium Pharmaceuticals, Inc.
 2017-03-05 PHASE1
NCT03093831 TERMINATED
Lymphoma, B-Cell, Marginal Zone
National Cancer Centre, Singapore
 2016-07-08 PHASE2
NCT02406742 COMPLETED
Leukemia, Lymphocytic, Chronic, B-Cell
Celgene
 2015-07-27 PHASE1; PHASE2
NCT02735876 WITHDRAWN
Mantle Cell Lymphoma
Acerta Pharma BV
 2016-05 PHASE3
NCT02747732 UNKNOWN
Diffuse Large B Cell Lymphoma; Primary Mediastinal (Thymic) Large B-cell Lymphoma; Transformed Indolent Lymphoma; Recurrent Disease; Refractory Cancer
Meirav Kedmi MD
 2016-12 PHASE2
NCT02670616 COMPLETED
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
Samsung Medical Center
 2016-05-01 PHASE2
NCT03045328 COMPLETED
Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
Steven E. Coutre
 2017-09-26 PHASE2
NCT03112603 COMPLETED
Graft-versus-host Disease (GVHD)
Incyte Corporation
 2017-06-29 PHASE3
NCT02301156 COMPLETED
Chronic Lymphocytic Leukemia
TG Therapeutics, Inc.
 2015-01-27 PHASE3
NCT02959944 COMPLETED
Chronic Graft Versus Host Disease
Pharmacyclics LLC.
 2017-05-11 PHASE3
NCT02537613 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute
 2015-12 PHASE1
NCT01644253 TERMINATED
Chronic Lymphocytic Leukemia; Peripheral T-cell Lymphoma
Aptevo Therapeutics
 2012-09 PHASE1
NCT03525925 COMPLETED
Metastatic Malignant Solid Neoplasm
Ohio State University Comprehensive Cancer Center
 2018-07-18 PHASE1
NCT04043845 WITHDRAWN
Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma
Dana-Farber Cancer Institute
 2020-02-03 PHASE1
NCT03572634 TERMINATED
Chronic Lymphocytic Leukemia; CLL; SLL; Small Lymphocytic Lymphoma
Sumitomo Pharma America, Inc.
 2019-06-10 PHASE1; PHASE2
NCT02460276 COMPLETED
Relapsed/Refractory Mantle Cell Lymphoma
Lund University Hospital
 2015-04 PHASE2
NCT03332498 COMPLETED
Colon Cancer; Colorectal Cancer; Colorectal Carcinoma; Colon Disease
H. Lee Moffitt Cancer Center and Research Institute
 2018-01-24 PHASE1; PHASE2
NCT03827603 UNKNOWN
AIHA - Warm Autoimmune Hemolytic Anemia
Eugene Nikitin
 2017-02-21 PHASE2
NCT02682641 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
 2016-05-18 PHASE2
NCT02950038 WITHDRAWN
Lung Cancer, Nonsmall Cell, Stage I
M.D. Anderson Cancer Center
 2016-12 PHASE2
NCT02562898 COMPLETED
Metastatic Pancreatic Adenocarcinoma
Margaret Tempero
 2015-10-12 PHASE1; PHASE2
NCT02165397 COMPLETED
Waldenström's Macroglobulinemia
Pharmacyclics LLC.
 2014-07-07 PHASE3
NCT02611908 WITHDRAWN
Chronic Lymphocytic Leukemia
Michael Choi
 2016-06 PHASE1
NCT02514083 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
National Heart, Lung, and Blood Institute (NHLBI)
 2015-12-09 PHASE2
NCT02006485 COMPLETED
Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
TG Therapeutics, Inc.
 2013-12-13 PHASE1
NCT02943473 TERMINATED
High Risk Smoldering Multiple Myeloma
Icahn School of Medicine at Mount Sinai
 2017-05-18 PHASE2
NCT03359460 COMPLETED
Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory High Risk Myelodysplastic Syndrome; Secondary Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome
University of California, Davis
 2017-12-01 PHASE1
NCT02614508 TERMINATED
Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
Emory University
 2016-01 PHASE1
NCT02874404 COMPLETED
Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
University of Nebraska
 2016-10-07 PHASE2
NCT02966730 TERMINATED
Follicular Lymphoma; Follicular Lymphoma, Grade 1; Follicular Lymphoma, Grade 2; Follicular Lymphoma Grade IIIa
Memorial Sloan Kettering Cancer Center
 2016-11 EARLY_PHASE1
NCT02759016 COMPLETED
Leukemia, Lymphocytic, Chronic, B-Cell
Boehringer Ingelheim
 2016-06-23 PHASE1
NCT02553941 COMPLETED
Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation; Secondary Myelodysplastic Syndrome
Brian Jonas
 2016-05-17 PHASE1
NCT02558816 COMPLETED
Mantle Cell Lymphoma
Nantes University Hospital
 2015-10-14 PHASE1; PHASE2
NCT02780830 WITHDRAWN
Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma; Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
AstraZeneca
 2016-06 PHASE1
NCT02575300 COMPLETED
Carcinoid Tumors; Pancreatic NET
H. Lee Moffitt Cancer Center and Research Institute
 2015-10-09 PHASE2
NCT02863718 COMPLETED
Chronic Lymphocytic Leukemia
German CLL Study Group
 2014-04-30 PHASE3
NCT02733042 COMPLETED
Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell
Celgene
 2016-05-11 PHASE1; PHASE2
NCT01962792 COMPLETED
Multiple Myeloma
Pharmacyclics LLC.
 2013-12 PHASE1; PHASE2
NCT02801578 COMPLETED
Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
 2016-07-06 PHASE2; PHASE3
NCT01611090 COMPLETED
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
 2012-09-19 PHASE3
NCT02352558 COMPLETED
Hematologic Malignancy
Sumitomo Pharma America, Inc.
 2015-05 PHASE1
NCT02973399 TERMINATED
Cancer
Esanex Inc.
 2017-02-07 PHASE1
NCT02912754 UNKNOWN
Leukemia, Lymphocytic, Chronic, B-Cell
Sunnybrook Health Sciences Centre
 2017-03 PHASE1; PHASE2
NCT02950220 COMPLETED
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Mediastinal Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Burkitt Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Burkitt Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma
Kami Maddocks
 2017-01-12 PHASE1
NCT03149315 COMPLETED
Food Allergy; Anaphylaxis Food
Ann & Robert H Lurie Children's Hospital of Chicago
 2017-04-10 PHASE2
NCT02692248 COMPLETED
Diffuse Large B-Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
 2016-04-07 PHASE2
NCT02557516 TERMINATED
Chronic Lymphocytic Leukemia
Innate Pharma
 2015-11-09 PHASE1; PHASE2
NCT02902965 COMPLETED
Multiple Myeloma
Pharmacyclics Switzerland GmbH
 2016-09-20 PHASE2
NCT02048813 ACTIVE_NOT_RECRUITING
Anemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
 2014-03-10 PHASE3
NCT02640209 TERMINATED
LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
University of Pennsylvania
 2016-01-29 EARLY_PHASE1
NCT02436668 COMPLETED
Metastatic Pancreatic Adenocarcinoma
Pharmacyclics LLC.
 2015-05 PHASE3
NCT02677948 WITHDRAWN
Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
University of Michigan Rogel Cancer Center
 2016-10 PHASE1; PHASE2
NCT02743546 WITHDRAWN
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell
Janssen Research & Development, LLC
 2016-07-20 PHASE1
NCT03145480 TERMINATED
Richter Syndrome
Northwell Health
 2017-06-19 PHASE2
NCT02556892 COMPLETED
Lymphocytic Leukemia
Janssen Pharmaceutical K.K.
 2015-07-03 PHASE1
NCT01886872 ACTIVE_NOT_RECRUITING
Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
 2014-01-15 PHASE3
NCT04754035 UNKNOWN
Chronic Lymphocytic Leukemia
Paolo Ghia
 2017-11-08 PHASE2
NCT03301207 COMPLETED
Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
 2017-10-20 PHASE1
NCT03280160 UNKNOWN
Chronic Lymphocytic Leukemia
PETHEMA Foundation
 2017-09-07 PHASE2
NCT02914327 WITHDRAWN
Cancer
Esanex Inc.
 2017-02-02 PHASE1
NCT02159755 ACTIVE_NOT_RECRUITING
Recurrent Mantle Cell Lymphoma
National Cancer Institute (NCI)
 2014-08-13 PHASE1
NCT02548962 TERMINATED
Multiple Myeloma
Pharmacyclics LLC.
 2016-03 PHASE1; PHASE2
NCT02269085 TERMINATED
Lymphoma
M.D. Anderson Cancer Center
 2015-04-20 PHASE1
NCT02268851 COMPLETED
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Mantle Cell Lymphoma
Dana-Farber Cancer Institute
 2014-11 PHASE1
NCT02232386 COMPLETED
Chronic Lymphocyte Leukemia; Adult Patients
Gruppo Italiano Malattie EMatologiche dell'Adulto
 2015-03-02 PHASE2
NCT02264574 COMPLETED
Chronic Lymphocytic Leukemia; Small-Cell Lymphoma
Pharmacyclics LLC.
 2014-10-06 PHASE3
NCT01855750 COMPLETED
Lymphoma
Janssen Research & Development, LLC
 2013-09-03 PHASE3
NCT02815059 WITHDRAWN
Acute Lymphoblastic Leukemia
University of Utah
 2016-09-28 PHASE1
NCT02272686 TERMINATED
Lymphoma
M.D. Anderson Cancer Center
 2016-06-03 PHASE2
NCT02055924 TERMINATED
B-cell Lymphoma
The Lymphoma Academic Research Organisation
 2014-05-26 PHASE1
NCT02757040 UNKNOWN
Leukemia, Lymphocytic, Chronic, B-Cell
Peking University People's Hospital
 2016-12 PHASE3
NCT01980654 COMPLETED
Follicular Lymphoma; B-cell Lymphoma; Non-Hodgkin's Lymphoma
Pharmacyclics LLC.
 2013-12 PHASE2
NCT02401048 COMPLETED
Diffuse Large B-Cell Lymphoma; Follicular Lymphoma
Pharmacyclics LLC.
 2015-05 PHASE1; PHASE2
NCT02195869 COMPLETED
Graft Versus Host Disease
Pharmacyclics LLC.
 2014-07-14 PHASE1; PHASE2
NCT02142049 COMPLETED
Diffuse Large B Cell Lymphoma Relapsed; Diffuse Large B Cell Lymphoma Refractory
Pharmacyclics LLC.
 2014-05 PHASE1; PHASE2
NCT02403271 COMPLETED
Non-Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer
Pharmacyclics LLC.
 2015-03 PHASE1; PHASE2
NCT02635074 TERMINATED
Recurrent Adult Acute Myeloid Leukemia
Steven E. Coutre
 2016-11 PHASE1
NCT02689141 COMPLETED
Chronic Lymphocytic Leukemia
German CLL Study Group
 2016-02-04 PHASE2
NCT02219737 COMPLETED
CD20 Positive; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
 2014-09-12 PHASE1
NCT02666898 COMPLETED
Leukemia, Lymphocytic, Chronic, B-Cell
French Innovative Leukemia Organisation
 2015-10 PHASE2
NCT02351037 TERMINATED
Acute Myeloid Leukemia (AML)
Pharmacyclics LLC.
 2015-02 PHASE2
NCT02160015 ACTIVE_NOT_RECRUITING
Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
 2014-05-20 PHASE1
NCT02200848 TERMINATED
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Georgetown University
 2014-04 PHASE1
NCT02670317 TERMINATED
Lymphoma, B-Cell
Fondazione Italiana Linfomi - ETS
 2016-09 PHASE2
NCT02446236 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
Hackensack Meridian Health
 2015-06-18 PHASE1
NCT02877225 COMPLETED
Healthy
Janssen Research & Development, LLC
 2016-08-29 PHASE1
NCT02415608 TERMINATED
Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic Mastocytosis
Jason Robert Gotlib
 2015-03 PHASE2
NCT02169180 COMPLETED
Lymphoma, Mantle-cell
Janssen Pharmaceutical K.K.
 2014-08 PHASE2
NCT01614821 COMPLETED
Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
 2012-05 PHASE2
NCT02345863 COMPLETED
Chronic Lymphocytic Leucemia
German CLL Study Group
 2015-01-16 PHASE2
NCT02542514 COMPLETED
Primary Central Nervous Lymphoma; Intraocular Lymphoma
The Lymphoma Academic Research Organisation
 2015-09 PHASE2
NCT02841150 COMPLETED
Healthy
Janssen Research & Development, LLC
 2016-06 PHASE1
NCT01589302 ACTIVE_NOT_RECRUITING
Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory/Relapsed Chronic Lymphocytic Leukemia
Kami Maddocks, MD
 2012-05-21 PHASE2
NCT01980628 COMPLETED
Marginal Zone Lymphoma; B-cell Lymphoma
Pharmacyclics LLC.
 2013-12 PHASE2
NCT02381080 COMPLETED
B-Cell Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC
 2015-05-19 PHASE1
NCT01849263 ACTIVE_NOT_RECRUITING
Grade 3a Follicular Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Refractory Follicular Lymphoma
National Cancer Institute (NCI)
 2013-04-02 PHASE2
NCT01779791 COMPLETED
Lymphoma
Janssen Research & Development, LLC
 2013-04-17 PHASE2
NCT02455297 TERMINATED
Lymphoma, Mantle-Cell
Bayer
 2015-08-24 PHASE2
NCT02638116 COMPLETED
Healthy
Janssen Research & Development, LLC
 2016-01 PHASE1
NCT01973387 COMPLETED
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Janssen Research & Development, LLC
 2013-10-28 PHASE3
NCT02013128 COMPLETED
Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
TG Therapeutics, Inc.
 2014-01-06 PHASE1; PHASE2
NCT02129062 TERMINATED
Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1; Recurrent Adult Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
 2014-04 PHASE2
NCT02390609 COMPLETED
Healthy
Janssen Research & Development, LLC
 2015-03 PHASE1
NCT02109224 TERMINATED
Adult B Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Cutaneous B-Cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; HIV Infection; Intraocular Lymphoma; Multicentric Angiofollicular Lymphoid Hyperplasia; Nodal Marginal Zone Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Plasma Cell Myeloma; Small Intestinal Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
National Cancer Institute (NCI)
 2014-09 PHASE1
NCT01646021 COMPLETED
Mantle Cell Lymphoma
Janssen Research & Development, LLC
 2012-12-10 PHASE3
NCT01829568 ACTIVE_NOT_RECRUITING
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma
National Cancer Institute (NCI)
 2013-06-26 PHASE1
NCT01722487 COMPLETED
Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Pharmacyclics LLC.
 2013-03 PHASE3
NCT01599949 COMPLETED
Mantle Cell Lymphoma
Janssen Research & Development, LLC
 2012-08 PHASE2
NCT02271438 COMPLETED
Healthy
Janssen Research & Development, LLC
 2014-10 PHASE1
NCT01325701 COMPLETED
Diffuse Large Cell B-lymphoma
Pharmacyclics LLC.
 2011-05 PHASE2
NCT01569750 COMPLETED
CD20-positive B-cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
 2012-06-14 PHASE1
NCT01744691 COMPLETED
Chronic Lymphocytic Leukemia With 17p Deletion; Small Lymphocytic Lymphoma With 17p Deletion
Pharmacyclics LLC.
 2013-01 PHASE2
NCT01578707 COMPLETED
Relapsed or Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Pharmacyclics LLC.
 2012-06 PHASE3
NCT01969266 COMPLETED
Healthy Volunteer
Janssen Research & Development, LLC
 2013-10 PHASE1
NCT01674322 COMPLETED
Healthy Participants
Janssen Research & Development, LLC
 2012-08 PHASE1
NCT01626651 COMPLETED
Healthy
Janssen Research & Development, LLC
 2012-06 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-03-16)

Check the Ibrutinib (PCI-32765) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ibrutinib acts as a potent and irreversible inhibitor of Bruton's tyrosine kinase (BTK), binding directly to the kinase to block its auto-phosphorylation and inhibit downstream signaling cascades including the ERK1/2, PI3K, and NF-kappaB pathways. By suppressing these critical survival and proliferation signals, Ibrutinib disrupts tumor microenvironment interactions and induces cell death, providing the biochemical basis for its clinical evaluation in hematological malignancies such as chronic lymphocytic leukemia and small lymphocytic lymphoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.